Show simple item record

dc.contributor.authorHaddad, Ren_US
dc.contributor.authorCohen, EEWen_US
dc.contributor.authorVenkatachalam, Men_US
dc.contributor.authorYoung, Ken_US
dc.contributor.authorSingh, Pen_US
dc.contributor.authorShaw, JWen_US
dc.contributor.authorKorytowsky, Ben_US
dc.contributor.authorAbraham, Pen_US
dc.contributor.authorHarrington, KJen_US
dc.date.accessioned2020-03-24T12:34:18Z
dc.date.issued2020-01-29en_US
dc.identifier.citationJournal of medical economics, 2020, pp. 1 - 6en_US
dc.identifier.issn1369-6998en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3550
dc.identifier.eissn1941-837Xen_US
dc.identifier.doi10.1080/13696998.2020.1715414en_US
dc.description.abstractAim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model for three health states (progression-free, progressed disease, and death). Using overall survival and progression-free survival data from the nivolumab and investigator's choice (IC) arms of the CheckMate 141 study, the proportion of patients in each health state was estimated by parametric modeling over a 25-year period. Cost, utility, adverse event, and disease management data inputs were obtained from relevant literature and applied to patients in each health state. A scenario analysis was conducted assuming increased uptake of subsequent immunotherapies. A one-way deterministic sensitivity analysis assessed the impact of variation in multiple parameters. A probabilistic sensitivity analysis in which probabilistic distributions were applied to each input during 1,000 model iterations was also conducted.Results: Total costs incurred were higher with nivolumab ($101,552) than with IC ($38,067). Nivolumab was associated with a higher number of life-years (LY; 1.21) and quality-adjusted life-years (QALYs; 0.89), compared with IC (0.68 and 0.42, respectively). The incremental cost-effectiveness ratio for nivolumab compared with IC was $134,438 per QALY, and this remained qualitatively similar when increased uptake of subsequent immunotherapies was assumed ($129,603 per QALY). Sensitivity analyses supported these findings.Conclusions: These results suggest that, at a willingness-to-pay threshold of $150,000 per QALY, nivolumab is a cost-effective option for therapy of SCCHN in the US.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1 - 6en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleCost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/13696998.2020.1715414en_US
rioxxterms.licenseref.startdate2020-01-29en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of medical economicsen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/